All In Biotech

Drug Trial Radar · NCT07442630

Long-term Comparison of Pitavastatin/Ezetimibe and Pitavastatin in Patients With Hypercholesterolemia and Elevated Triglycerides

A Multicenter Study to Evaluate Efficacy and Safety

Last checked: Nov 20, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

88

Actual

Start

Aug 21, 2023

Primary completion

Jan 22, 2026

Study completion Nov 30, 2026

Sponsor

Lead sponsor
JW PharmaceuticalIndustry
Sponsor type
Industry
First posted
Mar 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, randomized, double-blind, phase Ⅳ study to evaluate the long-term efficacy and safety of Pitavastatin/Ezetimibe and Pitavastatin in patients with hypercholesterolemia with elevated triglycerides

Conditions

  • Hypercholesterolemia

Interventions

  • Pitavastatin 4mgDrug

    Administered as a fixed-dose combination tablet (Pitavastatin/Ezetimibe 4/10 mg) orally once daily for 52 weeks.

  • Ezetimibe 10 mgDrug

    Administered as a fixed-dose combination tablet (Pitavastatin/Ezetimibe 4/10 mg) orally once daily for 52 weeks.

  • Placebo (for Pitavastatin/Ezetimibe)Drug

    Administered as a matching placebo tablet identical in appearance to the Pitavastatin/Ezetimibe 4/10 mg fixed-dose combination, orally once daily for 52 weeks.

  • Placebo (for Pitavastatin)Drug

    Administered as a matching placebo tablet identical in appearance to Pitavastatin 4 mg monotherapy, orally once daily for 52 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change from baseline in LDL Cholesterol at Week 8 after the first dose of study treatmentTime frame: Baseline to week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Catholic University of Korea, Yeouido St. Mary's Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.